The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 745K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

10 articles for T Haikarainen


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Highly Potent and Isoform Selective Dual Site Binding Tankyrase/Wnt Signaling Inhibitors That Increase Cellular Glucose Uptake and Have Antiproliferative Activity.EBI
University of Bath
Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.EBI
University of Bath
Development and structural analysis of adenosine site binding tankyrase inhibitors.EBI
University of Oulu
Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.EBI
University of Oulu
Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.EBI
University of Bath
Evaluation and Structural Basis for the Inhibition of Tankyrases by PARP Inhibitors.EBI
University of Oulu
Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.EBI
University of Oulu
Screening and structural analysis of flavones inhibiting tankyrases.EBI
University of Oulu
Functional and Structural Characterization of Clinical-Stage Janus Kinase 2 Inhibitors Identifies Determinants for Drug Selectivity.EBI
Tampere University
Discovery of PDK1 kinase inhibitors with a novel mechanism of action by ultrahigh throughput screening.BDB
Merck Research Laboratories